ArticleBiochemical and biophysical research communications2008
Insulin-secreting L-cells for the treatment of insulin-dependent diabetes.
Article in Biochemical and biophysical research communications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Harnessing gut cells for functional insulin production: Strategies and challenges.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- Reprogramming Cells to Make Insulin.Journal of the Endocrine Society · 2019Review
- Engineering the gut for insulin replacement to treat diabetes.Journal of diabetes investigation · 2016Review
- Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells.Experimental cell research · 2015Article
- Therapeutic effects of a non-β cell bioartificial pancreas in diabetic mice.Transplantation · 2014Article
- Evaluation of insulin expression and secretion in genetically engineered gut K and L-cells.BMC biotechnology · 2012Article
- Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells.Biotechnology and bioengineering · 2012Article
- Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment.BMC biotechnology · 2011Article
- Development and characterization of a tissue engineered pancreatic substitute based on recombinant intestinal endocrine L-cells.Biotechnology and bioengineering · 2009Article
- A cell-based approach for diabetes treatment using engineered non-beta cells.Journal of diabetes science and technology · 2009Article
- Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.Frontiers in endocrinologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cell-based treatments for insulin-dependent diabetes (IDD) may provide more physiologic regulation of blood glucose levels than daily insulin injections, thereby reducing the occurrence of secondary complications associated with diabetes. An autologous cell source is especially attractive for regulatory and ethical reasons in addition to eliminating the need for immunosuppression. This study uses non-beta-cells, genetically modified for physiologic insulin secretion. Enteroendocrine L-cells, exhibit regulated secretion in response to physiologic stimuli and their endogenous products are fully compatible with prandial metabolism. Murine GLUTag L-cells were transfected with a plasmid co-expressing human insulin and neomycin resistance and the stable cell line, GLUTag-INS, was established. Secretion properties of GLUTag-INS cells were investigated in vitro through induced secretion tests using meat hydrolysate or 3-isobutyl-1-methylxanthine and forskolin as secretagogues. GLUTag-INS cells rapidly co-secreted recombinant insulin and endogenous glucagon-like peptide in response to metabolic cues from the surrounding medium and demonstrated efficient processing of proinsulin to insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.